TCGA-98-A53D-01A-32R-A262-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.620
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ANGIOGENESIS+0.530
- COAGULATION+0.520
- INFLAMMATORY_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.480
- MYOGENESIS+0.430
- KRAS_SIGNALING_UP+0.410
- IL2_STAT5_SIGNALING+0.390
- ALLOGRAFT_REJECTION+0.380
Top 10 suppressed
- E2F_TARGETS-0.690
- OXIDATIVE_PHOSPHORYLATION-0.570
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V1-0.550
- MTORC1_SIGNALING-0.470
- DNA_REPAIR-0.460
- PROTEIN_SECRETION-0.420
- GLYCOLYSIS-0.400
- MITOTIC_SPINDLE-0.280
- PEROXISOME-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013539 | — | cohortMD2 | 0.948 |
| 2 | TCGA-ZF-AA5P-01A-11R-A39I-07 | — | — | 0.937 |
| 3 | TCGA-4Z-AA7N-01A-11R-A39I-07 | — | — | 0.936 |
| 4 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.933 |
| 5 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.922 |
| 6 | TCGA-CN-4728-01A-01R-1436-07 | — | — | 0.920 |
| 7 | SRR8942976 | — | — | 0.917 |
| 8 | C3N-02237 | — | cohortA1 | 0.915 |
| 9 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.914 |
| 10 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.620 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| COAGULATION | 0.520 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |